View in EDS HTML Full Text PDF Full Text

Advanced disease and CD8+ TEMRA cells predict severe infections in multiple myeloma.

Saved in:
Bibliographic Details
Title: Advanced disease and CD8+ TEMRA cells predict severe infections in multiple myeloma.
Authors: Tranter E; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Berlin, Germany., Busch D; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Berlin, Germany., Heck C; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Berlin, Germany., Blau IW; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Berlin, Germany., Nogai A; Onkologische Schwerpunktpraxis Tiergarten, Berlin, Germany., Schiele P; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Berlin, Germany.; Berlin Institute of Health (BIH) at Charité Universitätsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Berlin, Germany., Meisel C; Berlin Institute of Health (BIH) at Charité Universitätsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Berlin, Germany.; Institute of Medical Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany.; Department of Immunology, Labor Berlin-Charité Vivantes GmbH, Berlin, Germany., Bullinger L; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Berlin, Germany.; German Cancer Consortium (DKTK) Partner Site Berlin, German Cancer Research Center (DKFZ), Heidelberg, Germany.; ECRC Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany., Frentsch M; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Berlin, Germany.; Berlin Institute of Health (BIH) at Charité Universitätsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Berlin, Germany., Na IK; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Berlin, Germany.; Berlin Institute of Health (BIH) at Charité Universitätsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Berlin, Germany.; German Cancer Consortium (DKTK) Partner Site Berlin, German Cancer Research Center (DKFZ), Heidelberg, Germany.; ECRC Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.
Source: Frontiers in immunology [Front Immunol] 2025 Feb 12; Vol. 16, pp. 1532645. Date of Electronic Publication: 2025 Feb 12 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40013147
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Advanced disease and CD8<superscript>+</superscript> TEMRA cells predict severe infections in multiple myeloma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Tranter+E%22">Tranter E</searchLink>; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Busch+D%22">Busch D</searchLink>; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Heck+C%22">Heck C</searchLink>; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Blau+IW%22">Blau IW</searchLink>; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Nogai+A%22">Nogai A</searchLink>; Onkologische Schwerpunktpraxis Tiergarten, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Schiele+P%22">Schiele P</searchLink>; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Berlin, Germany.; Berlin Institute of Health (BIH) at Charité Universitätsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Meisel+C%22">Meisel C</searchLink>; Berlin Institute of Health (BIH) at Charité Universitätsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Berlin, Germany.; Institute of Medical Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany.; Department of Immunology, Labor Berlin-Charité Vivantes GmbH, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Bullinger+L%22">Bullinger L</searchLink>; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Berlin, Germany.; German Cancer Consortium (DKTK) Partner Site Berlin, German Cancer Research Center (DKFZ), Heidelberg, Germany.; ECRC Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Frentsch+M%22">Frentsch M</searchLink>; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Berlin, Germany.; Berlin Institute of Health (BIH) at Charité Universitätsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Na+IK%22">Na IK</searchLink>; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Berlin, Germany.; Berlin Institute of Health (BIH) at Charité Universitätsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Berlin, Germany.; German Cancer Consortium (DKTK) Partner Site Berlin, German Cancer Research Center (DKFZ), Heidelberg, Germany.; ECRC Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101560960%22">Frontiers in immunology</searchLink> [Front Immunol] 2025 Feb 12; Vol. 16, pp. 1532645. <i>Date of Electronic Publication: </i>2025 Feb 12 (<i>Print Publication: </i>2025).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101560960 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1664-3224 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216643224%22">16643224 </searchLink><i>NLM ISO Abbreviation: </i>Front Immunol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40013147
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fimmu.2025.1532645
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1532645
    Titles:
      – TitleFull: Advanced disease and CD8+ TEMRA cells predict severe infections in multiple myeloma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Tranter E
      – PersonEntity:
          Name:
            NameFull: Busch D
      – PersonEntity:
          Name:
            NameFull: Heck C
      – PersonEntity:
          Name:
            NameFull: Blau IW
      – PersonEntity:
          Name:
            NameFull: Nogai A
      – PersonEntity:
          Name:
            NameFull: Schiele P
      – PersonEntity:
          Name:
            NameFull: Meisel C
      – PersonEntity:
          Name:
            NameFull: Bullinger L
      – PersonEntity:
          Name:
            NameFull: Frentsch M
      – PersonEntity:
          Name:
            NameFull: Na IK
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 12
              M: 02
              Text: 2025 Feb 12
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1664-3224
          Numbering:
            – Type: volume
              Value: 16
          Titles:
            – TitleFull: Frontiers in immunology
              Type: main
ResultId 1